HCA Healthcare Inc Stock (HCA) Moved Down by 8.49% on Apr 24: What Investors Need To Know
HCA Healthcare Inc (HCA) moved down by 8.49%. The Healthcare Services & Equipment sector is down by 0.81%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 0.40%; HCA Healthcare Inc (HCA) down 8.59%; Hims & Hers Health Inc (HIMS) up 9.33%.

What is driving HCA Healthcare Inc (HCA)’s stock price down today?
HCA Healthcare's stock experienced significant downward movement today, primarily influenced by its first quarter 2026 financial and operating results, which presented a mixed picture against market expectations. While the company reported an increase in revenues and diluted earnings per share, the overall performance appears to have disappointed investors on several key fronts.
A significant factor contributing to the negative sentiment was the adjusted EBITDA, which fell short of analyst projections. This suggests margin pressures, despite revenue growth. The company also faced operational headwinds, notably a weaker-than-expected seasonal volume for patient admissions. HCA Healthcare noted a substantial decline in respiratory-related admissions and emergency room visits, along with a decrease in both inpatient and outpatient surgeries compared to the prior year. These lower utilization trends, partly attributed to a winter storm in January, raised concerns about future growth assumptions.
Further impacting investor confidence was the company's decision to reaffirm its full-year 2026 guidance, rather than raising it. This cautious stance by management, coupled with the Q1 results, led to an earnings day reset of expectations, as some analysts may have anticipated a more optimistic outlook. The reaffirmed guidance midpoint for earnings per share and adjusted EBITDA also came in slightly below consensus estimates.
Concerns regarding the dynamic healthcare policy environment, including the anticipated impact of health insurance exchange reforms and the expiration of certain premium tax credits, likely further weighed on investor sentiment. Although Medicaid supplemental programs provided a temporary offset in the first quarter, the long-term outlook for these policy-driven payments remains a point of caution for the market. Some analyst firms had previously expressed concerns about HCA's valuation relative to potential policy headwinds and moderating growth drivers.
Technical Analysis of HCA Healthcare Inc (HCA)
Technically, HCA Healthcare Inc (HCA) shows a MACD (12,26,9) value of [-6.38], indicating a sell signal. The RSI at 39.21 suggests neutral condition and the Williams %R at -81.38 suggests oversold condition. Please monitor closely.
Fundamental Analysis of HCA Healthcare Inc (HCA)
HCA Healthcare Inc (HCA) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $75.60B, ranking 7 in the industry. The net profit is $6.78B, ranking 2 in the industry. Company Profile
Over the past month, multiple analysts have rated the company as Buy, with an average price target of $539.51, a high of $635.00, and a low of $373.21.
More details about HCA Healthcare Inc (HCA)
Company Specific Risks:
- HCA Healthcare's adjusted EBITDA and full-year guidance for 2026 missed analyst consensus, leading to a premarket stock decline of approximately 7% following its Q1 earnings report on April 24, 2026.
- The company reported a significant decline in Q1 2026 patient volumes, including a 42% year-over-year drop in respiratory-related admissions and a 32% decline in emergency room visits, primarily due to lower seasonal respiratory activity and a January winter storm.
- Adjusted EBITDA margin for Q1 2026 decreased by approximately 50 basis points year-over-year, indicating margin compression.
- HCA is facing ongoing scrutiny regarding its past acquisitions, with a shareholder proposal at the April 23, 2026 annual meeting requesting a report on the health consequences of these acquisitions, citing concerns over patient safety and regulatory censure.
Recommended Articles











